In Vitro -Generated Tc17 Cells Present a Memory Phenotype and Serve As a Reservoir of Tc1 Cells In Vivo
Memory CD8 T cells are ideal candidates for cancer immunotherapy because they can mediate long-term protection against tumors. However, the therapeutic potential of different -generated CD8 T cell effector subsets to persist and become memory cells has not been fully characterized. Type 1 CD8 T (Tc1...
Gespeichert in:
Veröffentlicht in: | Frontiers in immunology 2018-02, Vol.9, p.209-209 |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Memory CD8
T cells are ideal candidates for cancer immunotherapy because they can mediate long-term protection against tumors. However, the therapeutic potential of different
-generated CD8
T cell effector subsets to persist and become memory cells has not been fully characterized. Type 1 CD8
T (Tc1) cells produce interferon-γ and are endowed with high cytotoxic capacity, whereas IL-17-producing CD8
T (Tc17) cells are less cytotoxic but display enhanced self-renewal capacity. We sought to evaluate the functional properties of
-generated Tc17 cells and elucidate their potential to become long lasting memory cells. Our results show that
-generated Tc17 cells display a greater
persistence and expansion in response to secondary antigen stimulation compared to Tc1 cells. When transferred into recipient mice, Tc17 cells persist in secondary lymphoid organs, present a recirculation behavior consistent with central memory T cells, and can shift to a Tc1 phenotype. Accordingly, Tc17 cells are endowed with a higher mitochondrial spare respiratory capacity than Tc1 cells and express higher levels of memory-related molecules than Tc1 cells. Together, these results demonstrate that
-generated Tc17 cells acquire a central memory program and provide a lasting reservoir of Tc1 cells
, thus supporting the use of Tc17 lymphocytes in the design of novel and more effective therapies. |
---|---|
ISSN: | 1664-3224 1664-3224 |
DOI: | 10.3389/fimmu.2018.00209 |